CASC8 

CASC8 is developing a regenerative therapy for Heart Failure ,by replacing scar with viable new cardiac tissue

OWNER

Marc Hendrikx (See Profile)


Sector

Biotech

Stage

Development, market readiness, clinical trial

Country

Belgium


Patented technology: EP2258833B1

Expected market entry 2027

Growing target population worldwide

preclinical phase accomplished

additional IPR opportunities

Status

Approved

IP Type

Patent

Time

8 years

Countries

Belgium
France
Germany
Italy
Netherlands
Spain
Switzerland
United Kingdom

Coverage

The invention relates to a novel population of cardiac stem cells which are positive for aldehyde dehydrogenase activity, express CD34, and do not express c-kit or CD45. These cells are different from previously identified cardiac stem cells, mesenchymal stem cells or HSCs. The invention provides methods for isolating these cells and the use of these cells and expanded cell populations thereof for use in heart repair.

Know more of this patent

This information is confidential, do not share or copy.


Other files:

CASC8 scientific data

Under evaluation at least till: 31st of March 2023

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar